the british society for rheumatology
the british society for rheumatology Company Information
Company Number
03470316
Next Accounts
Sep 2025
Shareholders
-
Group Structure
View All
Industry
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
+1Registered Address
bride house, 18-20 bride lane, london, EC4Y 8EE
Website
http://rheumatology.org.ukthe british society for rheumatology Estimated Valuation
Pomanda estimates the enterprise value of THE BRITISH SOCIETY FOR RHEUMATOLOGY at £3.1m based on a Turnover of £4.8m and 0.64x industry multiple (adjusted for size and gross margin).
the british society for rheumatology Estimated Valuation
Pomanda estimates the enterprise value of THE BRITISH SOCIETY FOR RHEUMATOLOGY at £0 based on an EBITDA of £-774.5k and a 4.84x industry multiple (adjusted for size and gross margin).
the british society for rheumatology Estimated Valuation
Pomanda estimates the enterprise value of THE BRITISH SOCIETY FOR RHEUMATOLOGY at £21.3m based on Net Assets of £11.8m and 1.8x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
The British Society For Rheumatology Overview
The British Society For Rheumatology is a live company located in london, EC4Y 8EE with a Companies House number of 03470316. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in November 1997, it's largest shareholder is unknown. The British Society For Rheumatology is a mature, small sized company, Pomanda has estimated its turnover at £4.8m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
The British Society For Rheumatology Health Check
Pomanda's financial health check has awarded The British Society For Rheumatology a 5 rating. We use a traffic light system to show it exceeds the industry average on 8 measures and has 1 areas for improvement. Company Health Check FAQs
8 Strong
3 Regular
1 Weak
Size
annual sales of £4.8m, make it larger than the average company (£3.4m)
£4.8m - The British Society For Rheumatology
£3.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 10%, show it is growing at a faster rate (6.5%)
10% - The British Society For Rheumatology
6.5% - Industry AVG
Production
with a gross margin of 40.4%, this company has a comparable cost of product (40.4%)
40.4% - The British Society For Rheumatology
40.4% - Industry AVG
Profitability
an operating margin of -17.9% make it less profitable than the average company (5.3%)
-17.9% - The British Society For Rheumatology
5.3% - Industry AVG
Employees
with 40 employees, this is above the industry average (32)
40 - The British Society For Rheumatology
32 - Industry AVG
Pay Structure
on an average salary of £52.7k, the company has an equivalent pay structure (£48k)
£52.7k - The British Society For Rheumatology
£48k - Industry AVG
Efficiency
resulting in sales per employee of £120.9k, this is equally as efficient (£139.9k)
£120.9k - The British Society For Rheumatology
£139.9k - Industry AVG
Debtor Days
it gets paid by customers after 22 days, this is earlier than average (49 days)
22 days - The British Society For Rheumatology
49 days - Industry AVG
Creditor Days
its suppliers are paid after 55 days, this is slower than average (36 days)
55 days - The British Society For Rheumatology
36 days - Industry AVG
Stock Days
it holds stock equivalent to 0 days, this is less than average (39 days)
0 days - The British Society For Rheumatology
39 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 139 weeks, this is more cash available to meet short term requirements (29 weeks)
139 weeks - The British Society For Rheumatology
29 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 10.8%, this is a lower level of debt than the average (50.6%)
10.8% - The British Society For Rheumatology
50.6% - Industry AVG
THE BRITISH SOCIETY FOR RHEUMATOLOGY financials
The British Society For Rheumatology's latest turnover from December 2023 is £4.8 million and the company has net assets of £11.8 million. According to their latest financial statements, The British Society For Rheumatology has 40 employees and maintains cash reserves of £3.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4,835,362 | 5,435,467 | 4,901,264 | 3,630,159 | 5,432,233 | 5,631,194 | 5,109,920 | 3,803,685 | 4,047,449 | 3,134,332 | 3,081,551 | 2,968,411 | 2,906,133 | 2,804,605 | 2,710,031 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | 65,090 | ||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | -614,345 | -354,153 | 1,589,610 | 65,090 | 1,181,860 | 1,383,892 | 1,356,162 | 45,740 | 544,980 | 30,332 | 272,954 | 49,768 | 485,192 | 563,744 | 403,079 |
| Tax | |||||||||||||||
| Profit After Tax | -614,345 | -354,153 | 1,589,610 | 65,090 | 1,181,860 | 1,383,892 | 1,356,162 | 45,740 | 544,980 | 30,332 | 272,954 | 49,768 | 485,192 | 563,744 | 403,079 |
| Dividends Paid | |||||||||||||||
| Retained Profit | -614,345 | -354,153 | 1,589,610 | 65,090 | 1,181,860 | 1,383,892 | 1,356,162 | 45,740 | 544,980 | 30,332 | 272,954 | 49,768 | 485,192 | 563,744 | 403,079 |
| Employee Costs | 2,108,833 | 1,771,135 | 1,528,310 | 1,494,496 | 1,462,670 | 1,337,539 | 1,293,620 | 1,356,055 | 1,246,639 | 1,222,865 | 1,043,710 | 968,689 | 857,418 | 753,218 | 818,901 |
| Number Of Employees | 40 | 40 | 32 | 26 | 30 | 30 | 29 | 26 | 26 | 25 | 24 | 24 | 25 | 24 | 21 |
| EBITDA* | 185,808 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,531,384 | 1,319,388 | 2,400,989 | 2,434,248 | 2,554,968 | 2,343,389 | 2,454,428 | 1,976,640 | 2,022,884 | 2,073,933 | 2,113,332 | 2,170,941 | 2,221,899 | 2,192,756 | 2,242,584 |
| Intangible Assets | 232,404 | 156,252 | 144,500 | 144,500 | 144,500 | 93,000 | 93,000 | 93,000 | |||||||
| Investments & Other | 6,698,525 | 6,020,863 | 5,408,632 | 4,605,079 | 4,202,885 | 3,455,022 | 2,628,999 | 2,419,252 | 2,192,898 | 661,452 | 631,120 | 564,018 | 609,059 | 640,536 | 606,763 |
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 8,462,313 | 7,340,251 | 7,809,621 | 7,039,327 | 6,757,853 | 5,954,663 | 5,227,927 | 4,540,392 | 4,360,282 | 2,828,385 | 2,837,452 | 2,827,959 | 2,830,958 | 2,833,292 | 2,849,347 |
| Stock & work in progress | 262 | 262 | 262 | 262 | 262 | 262 | 262 | 262 | 262 | 328 | 478 | 629 | 705 | 1,085 | 1,462 |
| Trade Debtors | 293,399 | 397,298 | 933,798 | 420,688 | 950,739 | 479,758 | 1,574,051 | 512,657 | 467,325 | 399,187 | 90,170 | 493,485 | 416 | 476,915 | 974,237 |
| Group Debtors | 38 | 161 | 20,175 | 620 | |||||||||||
| Misc Debtors | 641,051 | 831,918 | 513,426 | 562,004 | 584,122 | 910,544 | 660,829 | 566,064 | 579,487 | 328,367 | 583,923 | 372,575 | 1,127,249 | 221,395 | 400,668 |
| Cash | 3,858,940 | 5,661,781 | 5,077,179 | 4,077,399 | 4,485,310 | 3,880,610 | 2,953,847 | 2,560,862 | 2,664,878 | 3,497,153 | 3,306,588 | 3,111,448 | 2,204,038 | 2,256,378 | 1,297,488 |
| misc current assets | 499 | ||||||||||||||
| total current assets | 4,793,652 | 6,891,259 | 6,524,665 | 5,060,353 | 6,020,433 | 5,271,174 | 5,188,989 | 3,639,845 | 3,711,952 | 4,225,035 | 3,981,696 | 3,978,298 | 3,332,408 | 2,975,948 | 2,674,475 |
| total assets | 13,255,965 | 14,231,510 | 14,334,286 | 12,099,680 | 12,778,286 | 11,225,837 | 10,416,916 | 8,180,237 | 8,072,234 | 7,053,420 | 6,819,148 | 6,806,257 | 6,163,366 | 5,809,240 | 5,523,822 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 440,898 | 668,375 | 186,178 | 196,779 | 147,336 | 195,586 | 353,914 | 131,464 | 212,017 | 130,583 | 297,959 | 178,440 | 199,250 | 15,521 | 30,692 |
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 995,561 | 1,190,254 | 1,031,462 | 375,864 | 1,169,003 | 750,164 | 1,173,330 | 725,010 | 805,776 | 424,983 | 439,211 | 885,895 | 319,921 | 603,239 | 900,167 |
| total current liabilities | 1,436,459 | 1,858,629 | 1,217,640 | 572,643 | 1,316,339 | 945,750 | 1,527,244 | 856,474 | 1,017,793 | 555,566 | 737,170 | 1,064,335 | 519,171 | 618,760 | 930,859 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 1,436,459 | 1,858,629 | 1,217,640 | 572,643 | 1,316,339 | 945,750 | 1,527,244 | 856,474 | 1,017,793 | 555,566 | 737,170 | 1,064,335 | 519,171 | 618,760 | 930,859 |
| net assets | 11,819,506 | 12,372,881 | 13,116,646 | 11,527,037 | 11,461,947 | 10,280,087 | 8,889,672 | 7,323,763 | 7,054,441 | 6,497,854 | 6,081,978 | 5,741,922 | 5,644,195 | 5,190,480 | 4,592,963 |
| total shareholders funds | 11,819,506 | 12,372,881 | 13,116,646 | 11,527,037 | 11,461,947 | 10,280,087 | 8,889,672 | 7,323,763 | 7,054,441 | 6,497,854 | 6,081,978 | 5,741,922 | 5,644,195 | 5,190,480 | 4,592,963 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 65,090 | ||||||||||||||
| Depreciation | 81,862 | 82,261 | 109,976 | 120,718 | 121,048 | 114,975 | 79,382 | 57,817 | 58,978 | 63,502 | 65,394 | 64,398 | 63,061 | 69,785 | 59,136 |
| Amortisation | 7,907 | ||||||||||||||
| Tax | |||||||||||||||
| Stock | -66 | -150 | -151 | -76 | -380 | -377 | 1,462 | ||||||||
| Debtors | -294,766 | -218,008 | 464,532 | -552,169 | 144,559 | -844,578 | 1,156,159 | 31,909 | 319,258 | 53,423 | -192,090 | -261,444 | 409,180 | -657,040 | 1,375,525 |
| Creditors | -227,477 | 482,197 | -10,601 | 49,443 | -48,250 | -158,328 | 222,450 | -80,553 | 81,434 | -167,376 | 119,519 | -20,810 | 183,729 | -15,171 | 30,692 |
| Accruals and Deferred Income | -194,693 | 158,792 | 655,598 | -793,139 | 418,839 | -423,166 | 448,320 | -80,766 | 380,793 | -14,228 | -446,684 | 565,974 | -283,318 | -296,928 | 900,167 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -5,719 | ||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | -855,194 | -575,014 | 150,523 | ||||||||||||
| Change in Investments | 677,662 | 612,231 | 803,553 | 402,194 | 747,863 | 826,023 | 209,747 | 226,354 | 1,531,446 | 30,332 | 67,102 | -45,041 | -31,477 | 33,773 | 606,763 |
| cash flow from investments | -677,662 | -612,231 | -803,553 | -402,194 | -747,863 | -1,681,217 | -784,761 | -75,831 | -1,531,446 | -30,332 | |||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | 60,970 | -389,612 | -1 | 6,523 | 209,747 | 223,582 | 11,607 | 385,544 | 67,102 | 47,959 | -31,477 | 33,773 | 4,189,884 | ||
| cash and cash equivalents | |||||||||||||||
| cash | -1,802,841 | 584,602 | 999,780 | -407,911 | 604,700 | 926,763 | 392,985 | -104,016 | -832,275 | 190,565 | 195,140 | 907,410 | -52,340 | 958,890 | 1,297,488 |
| overdraft | |||||||||||||||
| change in cash | -1,802,841 | 584,602 | 999,780 | -407,911 | 604,700 | 926,763 | 392,985 | -104,016 | -832,275 | 190,565 | 195,140 | 907,410 | -52,340 | 958,890 | 1,297,488 |
the british society for rheumatology Credit Report and Business Information
The British Society For Rheumatology Competitor Analysis
Perform a competitor analysis for the british society for rheumatology by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in EC4Y area or any other competitors across 12 key performance metrics.
the british society for rheumatology Ownership
THE BRITISH SOCIETY FOR RHEUMATOLOGY group structure
The British Society For Rheumatology has 1 subsidiary company.
Ultimate parent company
THE BRITISH SOCIETY FOR RHEUMATOLOGY
03470316
1 subsidiary
the british society for rheumatology directors
The British Society For Rheumatology currently has 11 directors. The longest serving directors include Dr Joanna Ledingham (May 2021) and Mr Clifford Hurst (Apr 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Joanna Ledingham | 62 years | May 2021 | - | Director | |
| Mr Clifford Hurst | United Kingdom | 62 years | Apr 2022 | - | Director |
| Dr Sophia Steer | 55 years | Apr 2022 | - | Director | |
| Dr Elizabeth Murphy | 63 years | Jun 2023 | - | Director | |
| Mr Wiliiam Gregory | 48 years | Jun 2023 | - | Director | |
| Professor Sarah Ryan | 60 years | Jun 2024 | - | Director | |
| Ms Caroline Chivers | United Kingdom | 47 years | Jun 2024 | - | Director |
| Dr Anastasia-Vasiliki Madenidou | 37 years | Jun 2024 | - | Director | |
| Dr Jacqueline Clinch | 57 years | Jun 2024 | - | Director | |
| Mr Nicholas Samuels | 55 years | Oct 2024 | - | Director |
P&L
December 2023turnover
4.8m
-11%
operating profit
-864.3k
0%
gross margin
40.4%
+4.51%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
11.8m
-0.04%
total assets
13.3m
-0.07%
cash
3.9m
-0.32%
net assets
Total assets minus all liabilities
Similar Companies
the british society for rheumatology company details
company number
03470316
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
74990 - Non-trading company
incorporation date
November 1997
age
28
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
MOORE KINGSTON SMITH LLP
address
bride house, 18-20 bride lane, london, EC4Y 8EE
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
BATES WELLS & BRAITHWAITE
the british society for rheumatology Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to the british society for rheumatology.
the british society for rheumatology Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for THE BRITISH SOCIETY FOR RHEUMATOLOGY. This can take several minutes, an email will notify you when this has completed.
the british society for rheumatology Companies House Filings - See Documents
| date | description | view/download |
|---|
